BioLife Solutions, Inc. $BLFS Stock Sold by Isthmus Partners LLC

Isthmus Partners LLC reduced its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 82.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,124 shares of the medical equipment provider’s stock after selling 115,863 shares during the period. Isthmus Partners LLC’s holdings in BioLife Solutions were worth $976,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its stake in shares of BioLife Solutions by 1.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,035,757 shares of the medical equipment provider’s stock worth $19,761,000 after buying an additional 10,587 shares during the last quarter. Bank of America Corp DE grew its stake in BioLife Solutions by 73.4% in the 1st quarter. Bank of America Corp DE now owns 904,103 shares of the medical equipment provider’s stock valued at $17,250,000 after buying an additional 382,776 shares during the last quarter. Royal Bank of Canada grew its stake in BioLife Solutions by 8.1% in the 1st quarter. Royal Bank of Canada now owns 885,298 shares of the medical equipment provider’s stock valued at $16,891,000 after buying an additional 66,010 shares during the last quarter. Granahan Investment Management LLC grew its stake in BioLife Solutions by 49.7% in the 1st quarter. Granahan Investment Management LLC now owns 722,057 shares of the medical equipment provider’s stock valued at $13,777,000 after buying an additional 239,701 shares during the last quarter. Finally, Stephens Investment Management Group LLC grew its stake in BioLife Solutions by 10.9% in the 1st quarter. Stephens Investment Management Group LLC now owns 673,129 shares of the medical equipment provider’s stock valued at $12,843,000 after buying an additional 66,242 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Stock Performance

BLFS opened at $38.61 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $39.76. The company has a market capitalization of $1.89 billion, a P/E ratio of 33.28 and a beta of 1.82. The stock has a fifty day moving average of $37.18 and a 200-day moving average of $30.00.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, August 6th. The medical equipment provider reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.88. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. The company had revenue of $28.47 million during the quarter, compared to analysts’ expectations of $27.80 million. On average, equities research analysts predict that BioLife Solutions, Inc. will post 0.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

BLFS has been the topic of several research analyst reports. Stephens reissued an “equal weight” rating and issued a $31.00 price target (down from $32.00) on shares of BioLife Solutions in a report on Monday, July 27th. Lake Street Capital cut BioLife Solutions from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $33.00 to $31.00 in a report on Wednesday, July 22nd. Benchmark downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Monday, August 10th. Maxim Group lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 22nd. Finally, Wall Street Zen lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research note on Saturday, July 25th. One analyst has rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $31.38.

About BioLife Solutions

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.